Forest Laboratories
Forest’s COPD drug approved in US
March 3, 2011Sales and Marketing COPD, Daliresp, Daxas, Forest, Forest Laboratories, chronic obstructive pulmonary disease, roflumilast
Daliresp (roflumilast) has been approved by the FDA to treat severe chronic obstructive pulmonary disease. Forest Laboratories’ once-daily pill is …
Forest depression candidate struggles against placebo
March 1, 2011Research and Development Forest, Forest Laboratories, Gedeon Richter, cariprazine, depression, major depressive disorder
An investigational antipsychotic drug being developed by Forest Laboratories and Budapest-based Gedeon Richter has failed to prove itself in phase …
Lundbeck issues Lexapro patent warning
November 3, 2010Sales and Marketing Azilect, Cipralex, Forest Laboratories, Lexapro, Lundbeck, Xenazine
Neurological disorder specialist Lundbeck has posted a modest growth in revenue for the third quarter, but warned the looming patent …
Almirall and Forest’s phase III COPD drug misses goal
November 3, 2010Research and Development Aclidinium bromide, Almirall, COPY, Forest, Forest Laboratories, chronic obstructive pulmonary disease
Almirall and Forest’s COPD drug aclidinium bromide has disappointed in a phase III trial by producing fewer benefits than found …
